With simultaneous filings for uveitis drug Luveniq in the U.S. and Europe, Lux Biosciences Inc. has done what few small, private biotechs have managed in today's tough economy: get a drug to market without the help of public funding or a big pharma partner. (BioWorld Today)

It didn't take long for 2007 start-up Flexion Therapeutics to begin attracting venture financing and prospective pharma partners, all drawn to the Woburn, Mass.-based firm's unique business model aimed at giving deprioritized early stage compounds a second chance. (BioWorld Today)

In pretty short order, the regulatory status of Somaxon Pharmaceuticals Inc.'s insomnia drug Silenor (doxepin) went from having an uncertain timeline to a PDUFA date only two months away, news that surprised Wall Street and sent the company's shares skyrocketing 81.8 percent Friday. (BioWorld Today)